Top

Published in:

01-03-2020 | Neuroblastoma

Clinical research tools in pediatric oncology: challenges and opportunities

Authors: Teresa de Rojas, Anouk Neven, Alexander J. Towbin, Fernando Carceller, Francisco Bautista, David Riedl, Samantha Sodergren, Anne-Sophie Darlington, Ana Fernandez-Teijeiro, Lucas Moreno

Published in: Cancer and Metastasis Reviews | Issue 1/2020

Abstract

Survival for childhood cancers has improved significantly over the last decades. However, patient outcomes have plateaued over the last decade for difficult-to-treat diseases. With high cure rates, decreasing long-term toxicities and sequelae remains crucial. Since many advances in childhood cancer research come from the adult oncology world, one of the key areas is improving the adaptation of tools that are essential for clinical trial conduct that were developed for adults into pediatrics. These include tools to evaluate toxicity, quality of life, radiological response, statistical methodology, or indicators of cancer care quality. In this review, we present ongoing international efforts to validate and adapt these tools for children and adolescents and discuss remaining challenges. These efforts will hopefully accelerate and improve the quality of pediatric oncology research in the upcoming years.

Gatta, G., Botta, L., Rossi, S., Aareleid, T., Bielska-Lasota, M., Clavel, J., et al. (2014). Childhood cancer survival in Europe 1999-2007: Results of EUROCARE-5-a population-based study. The Lancet Oncology, 15(1), 35–47. https://doi.org/10.1016/S1470-2045(13)70548-5.CrossRefPubMed

Trama, A., Botta, L., Foschi, R., Ferrari, A., Stiller, C., Desandes, E., Maule, M. M., Merletti, F., Gatta, G., & EUROCARE-5 Working Group. (2016). Survival of European adolescents and young adults diagnosed with cancer in 2000-07: Population-based data from EUROCARE-5. The Lancet. Oncology, 17(7), 896–906. https://doi.org/10.1016/S1470-2045(16)00162-5.CrossRefPubMed

Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, C. K. (eds). (2018). SEER Cancer Statistics Review, 1975–2015, National Cancer Institute. Retrieved September 3, 2018, from https://seer.cancer.gov/csr/1975_2015/

The European Society for Paediatric Oncology. (2015). The SIOPE Strategic Plan; a European Cancer Plan for Children and Adolescents (1st ed.). SIOPE. Retrieved from https://www.siope.eu/SIOPE_StrategicPlan2015/files/assets/common/downloads/StrategyBooklet_UPDATEDFINAL.pdf

Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., et al. (2006). Chronic health conditions in adult survivors of childhood cancer. The New England Journal of Medicine, 355(15), 1572–1582. https://doi.org/10.1056/NEJMsa060185.CrossRefPubMed

Bhakta, N., Liu, Q., Ness, K. K., Baassiri, M., Eissa, H., Yeo, F., et al. (2017). The cumulative burden of surviving childhood cancer: An initial report from the St Jude Lifetime Cohort Study (SJLIFE). The Lancet, 390(10112), 2569–2582. https://doi.org/10.1016/S0140-6736(17)31610-0.CrossRef

Vassal, G., Rousseau, R., Blanc, P., Moreno, L., Bode, G., Schwoch, S., et al. (2015). Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. European journal of cancer (Oxford, England : 1990), 51(2), 218–224. https://doi.org/10.1016/j.ejca.2014.10.029.CrossRef

Vassal, G., Zwaan, C. M., Ashley, D., Le Deley, M. C., Hargrave, D., Blanc, P., & Adamson, P. C. (2013). New drugs for children and adolescents with cancer: The need for novel development pathways. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(13)70013-5.

Boklan, J. (2006). Little patients, losing patience: Pediatric cancer drug development. Molecular Cancer Therapeutics, 5(8), 1905–1908. https://doi.org/10.1158/1535-7163.MCT-06-0179.CrossRefPubMed

10.

Vassal, G., Fitzgerald, E., Schrappe, M., Arnold, F., Kowalczyk, J., Walker, D., et al. (2014). Challenges for children and adolescents with cancer in Europe: The SIOP-Europe agenda. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.25044.

11.

Vassal, G., Geoerger, B., & Morland, B. (2013). Is the European Pediatric Medicine Regulation working for children and adolescents with cancer? Clinical Cancer Research, 19(6), 1315–1325. https://doi.org/10.1158/1078-0432.CCR-12-2551.CrossRefPubMed

12.

Moreno, L., Pearson, A. D. J., Paoletti, X., Jimenez, I., Geoerger, B., Kearns, P. R., et al. (2017). Early phase clinical trials of anticancer agents in children and adolescents—An ITCC perspective. Nature Reviews. Clinical Oncology, 14(8), 497–507. https://doi.org/10.1038/nrclinonc.2017.59.CrossRefPubMed

13.

Institute, N. C (2010). Common Terminology Criteria for Adverse Events v4.3. NCI, NIH, DHHS. Retrieved from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf

14.

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376. https://doi.org/10.1093/jnci/85.5.365.CrossRefPubMed

15.

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute, 92(3), 205–216 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10655437.CrossRef

16.

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D., & Verweij, J. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228–247. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

17.

de Rojas, T., Bautista, F. J., Madero, L., & Moreno, L. (2016). The first step to integrating adapted common terminology criteria for adverse events for children. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 34(18), 2196–2197. https://doi.org/10.1200/JCO.2016.67.7104.CrossRef

18.

Schmiegelow, K., Attarbaschi, A., Barzilai, S., Escherich, G., Frandsen, T. L., Halsey, C., et al. (2016). Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: A Delphi consensus. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(16)30035-3.

19.

Sodergren, S. C., Husson, O., Robinson, J., Rohde, G. E., Tomaszewska, I. M., Vivat, B., et al. (2017). Systematic review of the health-related quality of life issues facing adolescents and young adults with cancer. Quality of Life Research, 26, 1659–1672. https://doi.org/10.1007/s11136-017-1520-x.CrossRefPubMedPubMedCentral

20.

Litière, S., Collette, S., De Vries, E. G. E., Seymour, L., & Bogaerts, J. (2017). RECIST-learning from the past to build the future. Nature Reviews. Clinical Oncology, 14, 187–192. https://doi.org/10.1038/nrclinonc.2016.195.CrossRefPubMed

21.

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., et al. (2018). Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. New England Journal of Medicine, 378(8), 731–739. https://doi.org/10.1056/NEJMoa1714448.CrossRefPubMed

22.

McHugh, K., & Kao, S. (2003). Response evaluation criteria in solid tumours (RECIST): Problems and need for modifications in paediatric oncology? The British Journal of Radiology, 76(907), 433–436. https://doi.org/10.1259/bjr/15521966.CrossRefPubMed

23.

Moon, L., & McHugh, K. (2005). Advances in paediatric tumour imaging. Archives of Disease in Childhood, 90(6), 608–611. https://doi.org/10.1136/adc.2004.051193.CrossRefPubMedPubMedCentral

24.

Barnacle, A. M., & McHugh, K. (2006). Limitations with the Response Evaluation Criteria in Solid Tumors (RECIST) guidance in disseminated pediatric malignancy. Pediatric Blood & Cancer, 46(2), 127–134. https://doi.org/10.1002/pbc.20344.CrossRef

25.

Therasse, P., Eisenhauer, E. A., & Verweij, J. (2006). RECIST revisited: A review of validation studies on tumour assessment. European journal of cancer (Oxford, England : 1990), 42(8), 1031–1039. https://doi.org/10.1016/j.ejca.2006.01.026.CrossRef

26.

Carceller, F., Bautista, F. J., Fowkes, L. A., Marshall, L. V., Sirvent, S. I., Chisholm, J. C., Pearson, A. D., Koh, D. M., & Moreno, L. (2016). Response assessment in paediatric phase I trials according to RECIST guidelines: Survival outcomes, patterns of progression and relevance of changes in tumour measurements. Pediatric Blood & Cancer, 63(8), 1400–1406. https://doi.org/10.1002/pbc.26039.CrossRef

27.

Steliarova-Foucher, E., Colombet, M., Ries, L. A. G., Moreno, F., Dolya, A., Bray, F., et al. (2017). International incidence of childhood cancer, 2001–10: A population-based registry study. The Lancet Oncology, 18(6), 719–731. https://doi.org/10.1016/S1470-2045(17)30186-9.CrossRefPubMedPubMedCentral

28.

Brodeur, G. M., & Bagatell, R. (2014). Mechanisms of neuroblastoma regression. Nature Reviews. Clinical Oncology. https://doi.org/10.1038/nrclinonc.2014.168.

29.

Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., et al. (2014). Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 14(2), 92–107. https://doi.org/10.1038/nrc3655.CrossRefPubMedPubMedCentral

30.

Weeda, V. B., Aronson, D. C., Verheij, J., & Lamers, W. H. (2019). Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients. Pediatric Blood & Cancer, 66(2), e27475. https://doi.org/10.1002/pbc.27475.CrossRef

31.

Ferrari, A., Miceli, R., Meazza, C., Zaffignani, E., Gronchi, A., Piva, L., Collini, P., Podda, M., Massimino, M., Luksch, R., Cefalo, G., Terenziani, M., Spreafico, F., Polastri, D., Fossati-Bellani, F., Casanova, M., & Mariani, L. (2009). Soft tissue sarcomas of childhood and adolescence: The prognostic role of tumor size in relation to patient body size. Journal of Clinical Oncology, 27(3), 371–376. https://doi.org/10.1200/JCO.2007.15.4542.CrossRefPubMed

32.

Nguyen, R., McCarville, M. B., Sykes, A., Mao, S., Wu, J., Langham, M. R., & Furman, W. L. (2018). Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy. International Journal of Clinical Oncology, 23, 900–907. https://doi.org/10.1007/s10147-018-1285-4.CrossRefPubMed

33.

O’Neill, A. F., Towbin, A. J., Krailo, M. D., Xia, C., Gao, Y., McCarville, M. B., et al. (2017). Characterization of pulmonary metastases in children with hepatoblastoma treated on Children’s Oncology Group Protocol AHEP0731 (the treatment of children with all stages of hepatoblastoma): A report from the Children’s Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 35(30), 3465–3473. https://doi.org/10.1200/JCO.2017.73.5654.CrossRef

34.

Schoot, R. A., McHugh, K., van Rijn, R. R., Kremer, L. C. M., Chisholm, J. C., Caron, H. N., & Merks, J. H. M. (2013). Response assessment in pediatric rhabdomyosarcoma: Can Response Evaluation Criteria in Solid Tumors replace three-dimensional volume assessments? Radiology, 269(3), 870–878. https://doi.org/10.1148/radiol.13122607.CrossRefPubMed

35.

Bagatell, R., McHugh, K., Naranjo, A., Van Ryn, C., Kirby, C., Brock, P., et al. (2016). Assessment of primary site response in children with high-risk neuroblastoma: An International Multicenter Study. Journal of Clinical Oncology, 34(7), 740–746. https://doi.org/10.1200/JCO.2015.63.2042.CrossRefPubMedPubMedCentral

36.

Guenther, L. M., Rowe, R. G., Acharya, P. T., Swenson, D. W., Meyer, S. C., Clinton, C. M., et al. (2017). Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. Pediatric Blood & Cancer, e26896. https://doi.org/10.1002/pbc.26896.

37.

Park, J. R., Bagatell, R., Cohn, S. L., Pearson, A. D., Villablanca, J. G., Berthold, F., Burchill, S., Boubaker, A., McHugh, K., Nuchtern, J. G., London, W. B., Seibel, N. L., Lindwasser, O. W., Maris, J. M., Brock, P., Schleiermacher, G., Ladenstein, R., Matthay, K. K., & Valteau-Couanet, D. (2017). Revisions to the international neuroblastoma response criteria: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Journal of Clinical Oncology, 35(22), 2580–2587. https://doi.org/10.1200/JCO.2016.72.0177.CrossRefPubMedPubMedCentral

38.

Aghighi, M., Boe, J., Rosenberg, J., Von Eyben, R., Gawande, R. S., Petit, P., et al. (2016). Three-dimensional radiologic assessment of chemotherapy response in Ewing sarcoma can be used to predict clinical outcome. Radiology, 280(3), 905–915. https://doi.org/10.1148/radiol.2016151301.CrossRefPubMedPubMedCentral

39.

Trout, A. T., Towbin, A. J., Klingbeil, L., Weiss, B. D., & von Allmen, D. (2017). Single and multidimensional measurements underestimate neuroblastoma response to therapy. Pediatric Blood & Cancer, 64(1), 18–24. https://doi.org/10.1002/pbc.26159.CrossRef

40.

ped-RECIST - RECIST in pediatric trials? (n.d.). Retrieved October 17, 2019, from https://recist.eortc.org/work-in-progress/recist-in-pediatric-trials/

41.

Common Terminology Criteria for Adverse Events (CTCAE). (n.d.). Retrieved November 8, 2019, from https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

42.

Reeve, B. B., McFatrich, M., Pinheiro, L. C., Weaver, M. S., Sung, L., Withycombe, J. S., Baker, J. N., Mack, J. W., Waldron, M. K., Gibson, D., Tomlinson, D., Freyer, D. R., Mowbray, C., Jacobs, S., Palma, D., Martens, C. E., Gold, S. H., Jackson, K. D., & Hinds, P. S. (2017). Eliciting the child’s voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative. Pediatric Blood & Cancer, 64(3), e26261. https://doi.org/10.1002/pbc.26261.CrossRef

43.

Gipson, D. S., Kirkendall, E. S., Gumbs-Petty, B., Quinn, T., Steen, A., Hicks, A., McMahon, A., Nicholas, S., Zhao-Wong, A., Taylor-Zapata, P., Turner, M., Herreshoff, E., Jones, C., Davis, J. M., Haber, M., & Hirschfeld, S. (2017). Development of a pediatric adverse events terminology. Pediatrics, 139(1). https://doi.org/10.1542/peds.2016-0985.

44.

Ruland, C. M., Hamilton, G. A., & Schjødt-Osmo, B. (2009). The complexity of symptoms and problems experienced in children with cancer: A review of the literature. Journal of Pain and Symptom Management, 37(3), 403–418. https://doi.org/10.1016/j.jpainsymman.2008.03.009.CrossRefPubMed

45.

Kestler, S. A., & LoBiondo-Wood, G. (2012). Review of symptom experiences in children and adolescents with cancer. Cancer Nursing, 35(2), E31–E49. https://doi.org/10.1097/NCC.0b013e3182207a2a.CrossRefPubMed

46.

Hudson, M. M., Ness, K. K., Gurney, J. G., Mulrooney, D. A., Chemaitilly, W., Krull, K. R., Green, D. M., Armstrong, G. T., Nottage, K. A., Jones, K. E., Sklar, C. A., Srivastava, D. K., & Robison, L. L. (2013). Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA, 309(22), 2371–2381. https://doi.org/10.1001/jama.2013.6296.CrossRefPubMedPubMedCentral

47.

Heath, J. A., Clarke, N. E., Donath, S. M., McCarthy, M., Anderson, V. A., & Wolfe, J. (2010). Symptoms and suffering at the end of life in children with cancer: An Australian perspective. The Medical Journal of Australia, 192(2), 71–75 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20078405 .CrossRef

48.

U.S. Food and Drug Administration (FDA). (2009). Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Retrieved October 30, 2019, from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims

49.

Matza, L. S., Patrick, D. L., Riley, A. W., Alexander, J. J., Rajmil, L., Pleil, A. M., & Bullinger, M. (2013). Pediatric patient-reported outcome instruments for research to support medical product labeling: Report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 16(4), 461–479. https://doi.org/10.1016/j.jval.2013.04.004.CrossRef

50.

Pinheiro, L. C., McFatrich, M., Lucas, N., Walker, J. S., Withycombe, J. S., Hinds, P. S., Sung, L., Tomlinson, D., Freyer, D. R., Mack, J. W., Baker, J. N., & Reeve, B. B. (2018). Child and adolescent self-report symptom measurement in pediatric oncology research: A systematic literature review. Quality of Life Research, 27(2), 291–319. https://doi.org/10.1007/s11136-017-1692-4.CrossRefPubMed

51.

Anthony, S. J., Selkirk, E., Sung, L., Klaassen, R. J., Dix, D., Scheinemann, K., & Klassen, A. F. (2014). Considering quality of life for children with cancer: A systematic review of patient-reported outcome measures and the development of a conceptual model. Quality of Life Research, 23(3), 771–789. https://doi.org/10.1007/s11136-013-0482-x.CrossRefPubMed

52.

Varni, J. W., Limbers, C., & Burwinkle, T. M. (2007). Literature review: Health-related quality of life measurement in pediatric oncology: Hearing the voices of the children. Journal of Pediatric Psychology, 32(9), 1151–1163. https://doi.org/10.1093/jpepsy/jsm008.CrossRefPubMed

53.

Zhukovsky, D. S., Rozmus, C. L., Robert, R. S., Bruera, E., Wells, R. J., Chisholm, G. B., Allo, J. A., & Cohen, M. Z. (2015). Symptom profiles in children with advanced cancer: Patient, family caregiver, and oncologist ratings. Cancer, 121(22), 4080–4087. https://doi.org/10.1002/cncr.29597.CrossRefPubMedPubMedCentral

54.

Ravens-Sieberer, U., Karow, A., Barthel, D., & Klasen, F. (2014). How to assess quality of life in child and adolescent psychiatry. Dialogues in Clinical Neuroscience, 16(2), 147–158 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25152654.PubMedPubMedCentral

55.

Upton, P., Lawford, J., & Eiser, C. (2008). Parent–child agreement across child health-related quality of life instruments: A review of the literature. Quality of Life Research, 17(6), 895–913. https://doi.org/10.1007/s11136-008-9350-5.CrossRefPubMed

56.

Eiser, C., & Varni, J. W. (2013). Health-related quality of life and symptom reporting: Similarities and differences between children and their parents. European Journal of Pediatrics, 172(10), 1299–1304. https://doi.org/10.1007/s00431-013-2049-9.CrossRefPubMed

57.

Germain, N., Aballéa, S., & Toumi, M. (2019). Measuring health-related quality of life in young children: How far have we come? Journal of Market Access & Health Policy, 7(1), 1618661. https://doi.org/10.1080/20016689.2019.1618661.CrossRef

58.

Grange, A., Bekker, H., Noyes, J., & Langley, P. (2007). Adequacy of health-related quality of life measures in children under 5 years old: Systematic review. Journal of Advanced Nursing, 59(3), 197–220. https://doi.org/10.1111/j.1365-2648.2007.04333.x.CrossRefPubMed

59.

Riley, A. W. (2004). Evidence that school-age children can self-report on their health. Ambulatory Pediatrics, 4(4 SUPPL), 371–376. https://doi.org/10.1367/A03-178R.1.CrossRefPubMed

60.

Varni, J. W., Limbers, C. A., & Burwinkle, T. M. (2007). How young can children reliably and validly self-report their health-related quality of life? An analysis of 8,591 children across age subgroups with the PedsQL™ 4.0 Generic Core Scales. Health and Quality of Life Outcomes, 5. https://doi.org/10.1186/1477-7525-5-1.

61.

Mokkink, L. B., Terwee, C. B., Knol, D. L., Stratford, P. W., Alonso, J., Patrick, D. L., et al. (2010). The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: A clarification of its content. BMC Medical Research Methodology, 10. https://doi.org/10.1186/1471-2288-10-22.

62.

Klassen, A. F., Strohm, S. J., Maurice-Stam, H., & Grootenhuis, M. A. (2010). Quality of life questionnaires for children with cancer and childhood cancer survivors: A review of the development of available measures. Supportive Care in Cancer, 18(9), 1207–1217. https://doi.org/10.1007/s00520-009-0751-y.CrossRefPubMed

63.

Anthony, S. J., Selkirk, E., Sung, L., Klaassen, R. J., Dix, D., & Klassen, A. F. (2017). Quality of life of pediatric oncology patients: Do patient-reported outcome instruments measure what matters to patients? Quality of Life Research, 26(2), 273–281. https://doi.org/10.1007/s11136-016-1393-4.CrossRefPubMed

64.

Bleyer, A. (2005). The adolescent and young adult gap in cancer care and outcome. Current Problems in Pediatric and Adolescent Health Care, 35(5), 182–217. https://doi.org/10.1016/j.cppeds.2005.02.001.CrossRefPubMed

65.

Thomas, D. M., Albritton, K. H., & Ferrari, A. (2010). Adolescent and young adult oncology: An emerging field. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 28(32), 4781–4782. https://doi.org/10.1200/JCO.2010.30.5128.CrossRef

66.

Tricoli, J. V., & Bleyer, A. (2018, November 1). Adolescent and young adult cancer biology. Cancer Journal (United States). Lippincott Williams and Wilkins. https://doi.org/10.1097/PPO.0000000000000343.

67.

Ramphal, R., Aubin, S., Czaykowski, P., De Pauw, S., Johnson, A., McKillop, S., et al. (2016). Adolescent and young adult cancer: Principles of care. Current oncology (Toronto, Ont.), 23(3), 204–209. https://doi.org/10.3747/co.23.3013.CrossRef

68.

Kim, B., Patterson, P., & White, K. (2018). Developmental considerations of young people with cancer transitioning to adulthood. European Journal of Cancer Care, 27(6), e12836. https://doi.org/10.1111/ecc.12836.CrossRefPubMed

69.

Sansom-Daly, U. M., & Wakefield, C. E. (2013). Distress and adjustment among adolescents and young adults with cancer: An empirical and conceptual review. Translational pediatrics, 2(4), 167–197. https://doi.org/10.3978/j.issn.2224-4336.2013.10.06.CrossRefPubMedPubMedCentral

70.

Zebrack, B. J. (2011). Psychological, social, and behavioral issues for young adults with cancer. Cancer, 117(SUPPL. 10), 2289–2294. https://doi.org/10.1002/cncr.26056.CrossRefPubMed

71.

Adolescent and Young Adult Oncology Group. (2006). Care imperatives for adolescents and young adults with cancer. Report of the adolescent and young adult oncology group. Retrieved November 8, 2019, from https://www.cancer.gov/types/aya/research/ayao-august-2006.pdf

72.

Sodergren, S. C., Husson, O., Rohde, G. E., Tomasewska, I. M., Griffiths, H., Pessing, A., Yarom, N., Hooker, L., Din, A., Darlington, A. S., EORTC Quality of Life Group, & EORTC Quality of Life Group. (2018). Does age matter? A comparison of health-related quality of life issues of adolescents and young adults with cancer. European Journal of Cancer Care, 27(6), e12980. https://doi.org/10.1111/ecc.12980.CrossRefPubMed

73.

Thompson, K., Palmer, S., & Dyson, G. (2009). Adolescents & young adults: Issues in transition from active therapy into follow-up care. European Journal of Oncology Nursing, 13(3), 207–212. https://doi.org/10.1016/j.ejon.2009.05.001.CrossRefPubMed

74.

Sodergren, S. C., Husson, O., Rohde, G. E., Tomasewska, I. M., Vivat, B., Yarom, N., Griffiths, H., & Darlington, A. S. (2018). A life put on pause: An exploration of the health-related quality of life issues relevant to adolescents and young adults with cancer. Journal of Adolescent and Young Adult Oncology, 7(4), 453–464. https://doi.org/10.1089/jayao.2017.0110.CrossRefPubMed

75.

Varni, J. W., Burwinkle, T. M., Katz, E. R., Meeske, K., & Dickinson, P. (2002). The PedsQL™ in pediatric cancer. Cancer, 94(7), 2090–2106. https://doi.org/10.1002/cncr.10428.CrossRefPubMed

76.

Kendall, J. M. (2003, March). Designing a research project: Randomised controlled trials and their principles. Emergency Medicine Journal. https://doi.org/10.1136/emj.20.2.164.

77.

Bothwell, L. E., Greene, J. A., Podolsky, S. H., Jones, D. S., & Malina, D. (2016). Assessing the gold standard—Lessons from the history of RCTs. New England Journal of Medicine, 374(22), 2175–2181. https://doi.org/10.1056/NEJMms1604593.CrossRefPubMed

78.

Hilgers, R.-D., König, F., Molenberghs, G., & Senn, S. (2016). Design and analysis of clinical trials for small rare disease populations. Dis Res Treat, 1 Retrieved from www.rarediseasesjournal.com.

79.

Joseph, P. D., Craig, J. C., & Caldwell, P. H. Y. (2015). Clinical trials in children. British Journal of Clinical Pharmacology, 79(3), 357–369. https://doi.org/10.1111/bcp.12305.CrossRefPubMedPubMedCentral

80.

Jones, S. R., Carley, S., & Harrison, M. (2003, September). An introduction to power and sample size estimation. Emergency Medicine Journal. https://doi.org/10.1136/emj.20.5.453.

81.

Casali, P. G., Bruzzi, P., Bogaerts, J., Blay, J.-Y., & Rare Cancers Europe (RCE) Consensus Panel. (2015). Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper. Annals of oncology : official journal of the European Society for Medical Oncology, 26(2), 300–306. https://doi.org/10.1093/annonc/mdu459.CrossRef

82.

Biau, D. J., Kernéis, S., & Porcher, R. (2008). Statistics in brief: The importance of sample size in the planning and interpretation of medical research. Clinical Orthopaedics and Related Research. New York: Springer. https://doi.org/10.1007/s11999-008-0346-9.CrossRef

83.

Friedman, L. M., Furberg, C. D., & Demets, D. L. (2010). Fundamentals of clinical trials. Fundamentals of Clinical Trials. New York: Springer. https://doi.org/10.1007/978-1-4419-1586-3.CrossRef

84.

Kairalla, J. A., Coffey, C. S., Thomann, M. A., & Muller, K. E. (2012, August 23). Adaptive trial designs: A review of barriers and opportunities. Trials. https://doi.org/10.1186/1745-6215-13-145.

85.

Abdel-Rahman, S. M., Reed, M. D., Wells, T. G., & Kearns, G. L. (2007). Considerations in the rational design and conduct of phase I/II pediatric clinical trials: Avoiding the problems and pitfalls. Clinical Pharmacology and Therapeutics, 81(4), 483–494. https://doi.org/10.1038/sj.clpt.6100134.CrossRefPubMed

86.

Klassen, T. P., Hartling, L., Craig, J. C., & Offringa, M. (2008, August). Children are not just small adults: The urgent need for high-quality trial evidence in children. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0050172.

87.

Gagne, J. J., Thompson, L., O’Keefe, K., & Kesselheim, A. S. (2014). Innovative research methods for studying treatments for rare diseases: Methodological review. BMJ (Clinical research ed.), 349, g6802. https://doi.org/10.1136/bmj.g6802.CrossRef

88.

Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., et al. (2018). Adaptive designs in clinical trials: Why use them, and how to run and report them. BMC Medicine, 16(1), 29. https://doi.org/10.1186/s12916-018-1017-7.CrossRefPubMedPubMedCentral

89.

Kelly, L. E., Dyson, M. P., Butcher, N. J., Balshaw, R., London, A. J., Neilson, C. J., Junker, A., Mahmud, S. M., Driedger, S. M., & Wang, X. (2018). Considerations for adaptive design in pediatric clinical trials: Study protocol for a systematic review, mixed-methods study, and integrated knowledge translation plan. Trials, 19(1), 572. https://doi.org/10.1186/s13063-018-2934-7.CrossRefPubMedPubMedCentral

90.

Jack Lee, J., & Chu, C. T. (2012). Bayesian clinical trials in action. Statistics in Medicine, 31(25), 2955–2972. https://doi.org/10.1002/sim.5404.CrossRefPubMed

91.

European Medicines Agency. (2017). ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population.

92.

European Medicines Agency. (2006). Guideline On Clinical Trials In Small Populations. Retrieved from http://www.emea.eu.int

93.

Driscoll, J. J., & Rixe, O. (2009, September). Overall survival: Still the gold standard: Why overall survival remains the definitive end point in cancer clinical trials. Cancer Journal. https://doi.org/10.1097/PPO.0b013e3181bdc2e0.

94.

Devidas, M., & Anderson, J. R. (2013). Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia. Clinical Investigation, 3(9), 849–858. https://doi.org/10.4155/cli.13.71.CrossRef

95.

Fleming, T. R., & Powers, J. H. (2012). Biomarkers and surrogate endpoints in clinical trials. Statistics in Medicine, 31(25), 2973–2984. https://doi.org/10.1002/sim.5403.CrossRefPubMedPubMedCentral

96.

Molenberghs, G., & Orman, C. (n.d.). Surrogate endpoints: Application in pediatric clinical trials.

97.

Korn, E. L., McShane, L. M., & Freidlin, B. (2013). Statistical challenges in the evaluation of treatments for small patient populations. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3004018.

98.

de Rojas, T., Puertas, M., Bautista, F., de Prada, I., López-Pino, M. Á., Rivero, B., Gonzalez-San Segundo, C., Gonzalez-Vicent, M., Lassaletta, A., Madero, L., & Moreno, L. (2019). Improving the quality of care in the molecular era for children and adolescents with medulloblastoma. Clinical & Translational Oncology, 21, 1687–1698. https://doi.org/10.1007/s12094-019-02101-2.CrossRef

99.

Kowalczyk J, Samardakiewicz M, Kowalewska-Bajor M, Pomaska EA, Fitzgerald E, Essiaf S. (2011). European Standards of Care for Children with Cancer. Retrieved from http://www.siope.eu/wp-content/uploads/2013/09/European_Standards_final_2011.pdf

100.

From the American Academy of Pediatrics. (2014). Standards for pediatric cancer centers. Section on hematology/oncology. Pediatrics, 134, 410–414 Retrieved from http://pediatrics.aappublications.org/content/134/2/410.CrossRef

101.

Knops, R. R. G., Hulscher, M. E. J. L., Hermens, R. P. M. G., Hilbink-Smolders, M., Loeffen, J. L., Kollen, W. J. W., et al. (2012). High-quality care for all children with cancer. Annals of Oncology, 23(7), 1906–1911. https://doi.org/10.1093/annonc/mdr601.CrossRefPubMed

102.

Vlayen, J., Vrijens, F., Devriese, S., Beirens, K., Van Eycken, E., & Stordeur, S. (2012). Quality indicators for testicular cancer: A population-based study. European Journal of Cancer, 48(8), 1133–1140. https://doi.org/10.1016/j.ejca.2011.10.023.CrossRefPubMed

103.

Bradley, N. M. E., Robinson, P. D., Greenberg, M. L., Barr, R. D., Klassen, A. F., Chan, Y. L., & Greenberg, C. M. (2013). Measuring the quality of a childhood cancer care delivery system: Quality indicator development. Value in Health, 16(4), 647–654. https://doi.org/10.1016/J.JVAL.2013.03.1627.CrossRefPubMed

104.

de Rojas, T., Clementel, E., Giralt, J., Cruz, O., Boterberg, T., Kortmann, R.-D., et al. (2019). Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives. European Journal of Cancer, 114, 36–46. https://doi.org/10.1016/j.ejca.2019.03.018.CrossRefPubMed

105.

van der Graaf, W. T. A., Orbach, D., Judson, I. R., & Ferrari, A. (2017). Soft tissue sarcomas in adolescents and young adults: A comparison with their paediatric and adult counterparts. The Lancet Oncology, 18(3), e166–e175. https://doi.org/10.1016/S1470-2045(17)30099-2.CrossRefPubMed

Title: Clinical research tools in pediatric oncology: challenges and opportunities
Authors: Teresa de Rojas
Anouk Neven
Alexander J. Towbin
Fernando Carceller
Francisco Bautista
David Riedl
Samantha Sodergren
Anne-Sophie Darlington
Ana Fernandez-Teijeiro
Lucas Moreno
Publication date: 01-03-2020
Publisher: Springer US
Keywords: Neuroblastoma
Neuroblastoma
Pediatric Cancer
Published in: Cancer and Metastasis Reviews / Issue 1/2020
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-020-09856-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data

New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence

Genetic predisposition and chromosome instability in neuroblastoma

Professor Samuel C. Brooks, Jr., Ph.D. (1928–2019)

A systematic approach to the endocrine care of survivors of pediatric hematopoietic stem cell transplantation

Insights into the prenatal origin of childhood acute lymphoblastic leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer